- Home
- MBRX vs VINC Comparison
MBRX vs VINC Comparison
Compare MBRX & VINC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBRX
- VINC
- Stock Information
- Founded
- MBRX 2015
- VINC 2019
- Country
- MBRX United States
- VINC United States
- Employees
- MBRX N/A
- VINC N/A
- Industry
- MBRX Biotechnology: Pharmaceutical Preparations
- VINC Biotechnology: Pharmaceutical Preparations
- Sector
- MBRX Health Care
- VINC Health Care
- Exchange
- MBRX Nasdaq
- VINC Nasdaq
- Market Cap
- MBRX 5.7M
- VINC 6.2M
- IPO Year
- MBRX 2016
- VINC N/A
- Fundamental
- Price
- MBRX $1.88
- VINC $0.15
- Analyst Decision
- MBRX Strong Buy
- VINC Buy
- Analyst Count
- MBRX 2
- VINC 2
- Target Price
- MBRX $24.00
- VINC $2.00
- AVG Volume (30 Days)
- MBRX 62.3K
- VINC 21.3M
- Earning Date
- MBRX 11-08-2024
- VINC 11-12-2024
- Dividend Yield
- MBRX N/A
- VINC N/A
- EPS Growth
- MBRX N/A
- VINC N/A
- EPS
- MBRX N/A
- VINC N/A
- Revenue
- MBRX N/A
- VINC N/A
- Revenue This Year
- MBRX N/A
- VINC N/A
- Revenue Next Year
- MBRX N/A
- VINC N/A
- P/E Ratio
- MBRX N/A
- VINC N/A
- Revenue Growth
- MBRX N/A
- VINC N/A
- 52 Week Low
- MBRX $0.40
- VINC $0.14
- 52 Week High
- MBRX $6.24
- VINC $9.37
- Technical
- Relative Strength Index (RSI)
- MBRX 47.84
- VINC 37.12
- Support Level
- MBRX $1.65
- VINC $0.14
- Resistance Level
- MBRX $1.99
- VINC $0.52
- Average True Range (ATR)
- MBRX 0.20
- VINC 0.04
- MACD
- MBRX 0.04
- VINC -0.00
- Stochastic Oscillator
- MBRX 71.79
- VINC 3.25
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
About VINC Vincerx Pharma Inc.
Vincerx Pharma Inc is a clinical-stage biopharmaceutical company focused on development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The company's activities are conducted in the United States. It focuses on developing, using, manufacturing, commercializing, sublicensing, and distributing a clinical-stage and follow-on small molecule drug program and a preclinical-stage bioconjugation/next-generation ADC platform.